NON-HODGKIN LYMPHOMA,B CELL
Clinical trials for NON-HODGKIN LYMPHOMA,B CELL explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA,B CELL trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA,B CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study opens door for CAR t therapy in patients with kidney disease
Disease control Recruiting nowThis study looks at whether CAR T cell therapy, a type of cancer treatment that uses a patient's own immune cells, can be safely given to people with moderate to severe kidney problems. The trial involves 20 adults with blood cancers like lymphoma, myeloma, or leukemia. Before ge…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE2 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New CAR-T therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage study tests a new treatment called BRL-201 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to target cancer cells, and aims to control the disease. About 12-18 adults will participate to …
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE1 • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Off-the-Shelf cell therapy takes on tough lymphoma
Disease control Recruiting nowThis early study tests a one-time treatment using universal (off-the-shelf) CAR-T cells that target CD19, a protein on cancer cells. It is for adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have few options left. The main goal is to check safety and find the r…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Italian study tracks new antibody drugs for lymphoma patients
Knowledge-focused Recruiting nowThis study follows 1,500 people with B-cell non-Hodgkin lymphoma in Italy who are treated with newer monoclonal antibodies. Researchers will track how well the cancer responds, how long patients live without the disease getting worse, and any side effects. The goal is to see how …
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Muscle loss may predict CAR-T outcomes in lymphoma
Knowledge-focused Recruiting nowThis study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works or causes more side effects. The goal is to learn whether simpl…
Matched conditions: NON-HODGKIN LYMPHOMA,B CELL
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC